|MDACC Study No:||2011-0547 (clinicaltrials.gov NCT No: NCT01451437)|
|Title:||A Phase 1 Study to Evaluate the Safety and Tolerability and Pharmacokinetic/Pharmacodynamics of MK-8242 Administered Alone and in Combination with Chemotherapy in Subjects with Refractory, or Recurrent Acute Myelogenous Leukemia|
|Principal Investigator:||Farhad Ravandi-Kashani|
|Study Description:||The goal of this genetic sub-study is to look at how people's genes may |
influence if and how well the study drug may affect the disease. This is
called pharmacogenetic (PGt) testing.
The genetic research in this sub-study involves looking at samples of DNA (the
genetic material of cells) and bone marrow samples.